OakChart

ProKidney Corp

PROKHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

1.13+0.02 (1.80%)
2026-11-12 06:16 CET
Market cap
236.14 USD m
Revenue, TTM
0.82 USD m
Net income, TTM
-84.16 USD m
Free cash flow, TTM
-159.73 USD m
EPS diluted, TTM
-0.55
P/E
-
Compare

Price

PROK against its 20, 50 and 200-day averages
2050200earnings
1.001.502.004.7M9.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PROKclose 1.1320-day 1.3050-day 1.56200-day 1.781.1352w low

60.8% under the 52-week high of 2.88 on 12 Nov 2025. 52-week low 0.87 on 2 Nov 2026. Last 15 sessions, 83.3% high to low

Volume 0.41× normal · the line is the 50-bar volume average

Profile

PROK
52-week range, 13% of the way up
0.872.88

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

IndexRUT
Employees231
IPOJun 30, 2021
Beta1.91
ATR, 14d0.13
Rel volume0.41
Short float21.70%
Insider own46.34%
Inst own26.93%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap341.68M
Enterprise Value1.27B
Income-84.16M
Sales0.82M
Book/sh-4.29
Cash/sh0.60
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees231
IPOJun 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S416.68
P/B-
P/C1.88
P/FCF-
EV/EBITDA-
EV/Sales1548.79
Quick Ratio8.36
Current Ratio8.36
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.55
EPS next Y-0.69
EPS next Q-0.16
EPS this Y-31.76%
EPS next Y-1.01%
EPS next 5Y9.81%
EPS past 3/5Y33.55% 12.93%
Sales past 3/5Y- -
EPS Y/Y TTM2.13%
Sales Y/Y TTM55.22%
EPS Q/Q-20.38%
Sales Q/Q-32.13%
EarningsAug 10 AMC
EPS/Sales Surpr.-7.14% -19.48%

Ownership

Insider Own46.34%
Insider Trans-0.54%
Inst Own26.93%
Inst Trans1.86%
ROA-27.10%
ROE-
ROIC-
Gross Margin-600.61%
Oper. Margin-21664.55%
Profit Margin-10288.39%
SMA20-12.96%
SMA50-27.68%
SMA200-36.34%
Trades-

Technical

Shs Outstand205.72M
Shs Float112.13M
Short Float21.70%
Short Ratio16.61
Short Interest24.34M
52W High2.88 -60.76%
52W Low0.87 29.86%
Volatility10.73% 11.54%
ATR (14)0.13
RSI (14)36.51
Beta1.91
Rel Volume0.41
Avg Volume1.46M
Volume595,877

Performance

Perf Week0.89%
Perf Month-28.03%
Perf Quarter-19.57%
Perf Half Y-35.43%
Perf YTD-49.55%
Perf Year-59.64%
Perf 3Y-29.37%
Perf 5Y-88.62%
Perf 10Y-
Recom1.83
Target Price6.50
Prev Close1.11
Price1.13
Change %1.80%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Dec 16, 2025InitiatedHH.C. WainwrightBuy$12+961.9%
Jun 30, 2025DowngradeBBofA SecuritiesNeutral → Underperform$1-11.5%
Sep 30, 2024InitiatedJJP MorganNeutral
Sep 10, 2024InitiatedGGuggenheimBuy$6+431.0%
Mar 07, 2024ResumedMMorgan StanleyEqual-Weight$3+165.5%
Jan 02, 2024DowngradeBBofA SecuritiesBuy → Neutral
Jul 25, 2023InitiatedBBTIG ResearchBuy$16+1,315.9%
Dec 21, 2022InitiatedJJefferiesBuy$15+1,227.4%
Nov 10, 2022InitiatedMMorgan StanleyEqual-Weight$13+1,050.4%
Oct 18, 2022InitiatedUUBSBuy$18+1,492.9%

Peers

Mkt cap
TickerCompanyMkt cap
MAZEMaze Therapeutics Inc2.01B
CAPRCapricor Therapeutics Inc652.32M
VRTXVertex Pharmaceuticals Inc138.69B
VERAVera Therapeutics Inc2.20B
TVTXTravere Therapeutics Inc5.00B
MLYSMineralys Therapeutics Inc1.43B
ARDXArdelyx Inc786.79M
AZNAstrazeneca plc287.66B
AKBAAkebia Therapeutics Inc159.30M
DVADaVita Inc11.54B

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Pereira Brian JGDirectorAug 19 '26Sale1.44222,949321,203222,948Aug 20 05:00 PM
Pereira Brian JGDirectorAug 20 '26Sale1.42222,948316,5640Aug 20 05:00 PM
Pereira Brian JGDirectorAug 18 '26Sale1.37229,338314,468445,897Aug 20 05:00 PM
Pereira Brian JGDirectorAug 19 '26Sale1.4427,05138,97227,052Aug 20 05:00 PM
Pereira Brian JGDirectorAug 20 '26Sale1.4227,05238,4110Aug 20 05:00 PM
Pereira Brian JGDirectorAug 18 '26Sale1.3727,82638,15554,103Aug 20 05:00 PM
Brian PereiraDirectorAug 18 '26Proposed Sale1.40675,235945,329Aug 18 04:42 PM
Brian PereiraDirectorAug 18 '26Proposed Sale1.3981,929114,000Aug 18 04:41 PM
Pereira Brian JGDirectorNov 13 '25Sale2.37502,1361,190,0620Nov 14 04:07 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SURISimplify Propel Opportunities ETFAUM: 74.30M
IWCiShares Micro-Cap ETFAUM: 1.22B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
BBCVirtus Biotech Clinical Trials ETFAUM: 31.26M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B

News

latest 14 of 200
  • ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update (GlobeNewswire)
  • ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026 (GlobeNewswire)
  • ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026 (GlobeNewswire)
  • ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
  • ProKidney Appoints Kenneth Locke as Chief Technical Officer (GlobeNewswire)
  • ProKidney Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
  • ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer (GlobeNewswire)
  • ProKidney Reports Full Year 2025 Financial Results and Business Highlights (GlobeNewswire) -6.25%
  • Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +11.31%
  • ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.14%
  • ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright (Insider Monkey)
  • Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy (PR Newswire) +5.77%
  • ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates (GlobeNewswire) -6.57%
  • ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-10-0.150-0.140-0.1510.150.196
2026Q12026-05-15-0.140-0.138-0.1410.230.105
2025Q42026-03-18-0.140-0.147-0.1370.220.007
2025Q32025-11-10-0.120-0.133-0.1220.220.065
2025Q22025-08-12-0.130-0.145-0.1270.220.005
2025Q12025-05-12-0.130-0.156-0.1300.23-3
2024Q42025-03-17-0.160-0.148-0.1660.080.005
2024Q32024-11-12-0.140-0.128-0.1420.000.004
2024Q22024-08-09-0.160-0.253-0.1650.000.005
2024Q12024-05-10-0.160-0.293-0.1560.000.003
2023Q42024-03-21-0.090-0.170-0.0950.000.004
2023Q32023-11-14-0.180-0.158-0.1780.000.005
2023Q22023-08-10-0.140-0.394-0.1410.000.004
2023Q12023-05-11-0.160-0.391-0.1570.000.002
2022Q42023-03-28-0.110-0.245-0.1050.000.005
2022Q32022-11-14-0.130-0.235-0.1940.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-0.230-1.154-1.7560.000.00
2023FY-0.570-0.607-0.5750.000.00
2024FY-0.620-0.583-0.6250.080.00
2025FY-0.520-0.575-0.7220.890.54
2026FY--0.685--0.53
2027FY--0.692--0.49
2028FY--0.382--62.82
2029FY--0.283--128.6
2030FY-0.073--333.82

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-255000.120.000.20
2026Q3S2026-08-115030.120.000.20
2026Q3S2026-08-105000.150.000.23
2026Q3S2026-08-015000.150.000.23
2026Q3S2026-07-295100.150.000.23
2026Q3S2026-05-185210.150.000.23
2026Q3S2026-05-154110.130.000.23
2026Q3S2026-03-194000.120.000.20
2026Q3S2026-02-101000.200.200.20
2026Q3R2026-10-26300-0.16-0.24-0.12
2026Q3R2026-10-25310-0.16-0.24-0.12
2026Q3R2026-08-12330-0.16-0.24-0.12
2026Q3R2026-08-11320-0.17-0.24-0.13
2026Q3R2026-08-10310-0.18-0.24-0.15

Estimate history

EPS, annual-0.896-1.756-0.575-0.625-0.515-0.5525
Period20212022202320242025TTM
EPS, quarterly-0.165-0.142-0.166-0.13-0.127-0.122-0.137-0.141-0.152
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000.0760.8930.82
Period20212022202320242025TTM
Sales, quarterly000.0760.230.2210.2170.2250.2260.15
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual61.5461.5459.88128.054141.807205.716
Period20212022202320242025MRQ
Shares, quarterly125.857127.92128.054129.536133.419135.978141.807141.981205.716
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.820.890.080.000.000.00
Cost of Goods Sold Incl. D&A5.735.724.343.173.041.98
Gross Profit-4.91-4.83-4.26-3.17-3.04-1.98
Selling, General and Administrative Excl. Other172.30159.86174.09148.35149.9753.13
Research and Development130.91114.12127.67106.7182.0746.26
Other Operating Expense0.000.000.000.000.000.00
Operating Income-177.22-164.69-178.35-151.52-153.01-55.11
Interest Expense0.020.000.010.010.210.00
Unusual Expense0.000.325.320.000.000.00
Net Income Before Taxes-166.78-151.20-163.93-129.45-147.24-55.11
Income Taxes-1.020.41-0.606.000.900.04
Consolidated Net Income-165.75-151.61-163.34-135.45-148.13-55.15
Net Income From Continuing Operations-84.16-68.99-61.19-35.47-108.03-55.15
Net Income-84.16-68.99-61.19-35.47-108.03-55.15
EPS (Recurring)-0.45-0.51-0.59-0.57-1.76-0.90
EPS (Basic, Before Extraordinaries)-0.55-0.52-0.62-0.57-1.76-0.90
EPS (Diluted)-0.55-0.52-0.62-0.57-1.76-0.90
EBITDA-171.49-158.97-174.01-148.35-149.97-53.13
Non-Operating Income (Expense)10.4613.8119.7522.085.980.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense20.3220.0223.2024.3758.830.51
Price To Sales Ratio465.26335.982,177.35---
Gross Margin-600.61-540.76-5,606.58---
Operating Margin-21,664.55-18,442.22-234,673.68---
Net Margin-10,288.39-7,725.20-80,507.89---
Shares Outstanding205.72141.81128.0559.8861.5461.54
Market Capitalization236.14236.14216.27119.501,596.66315.71

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.150.230.230.220.220.230.080.00
Cost of Goods Sold Incl. D&A1.451.441.451.401.491.381.341.20
Gross Profit-1.30-1.21-1.22-1.18-1.27-1.15-1.26-1.20
Selling, General and Administrative Excl. Other47.0743.7244.1537.3638.4440.2344.9847.77
Research and Development36.0933.8434.1626.8225.8827.2639.7831.25
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-48.37-44.93-45.37-38.54-39.71-41.39-46.25-48.97
Interest Expense0.000.010.000.000.00-0.000.00
Unusual Expense0.000.000.000.000.000.005.320.00
Net Income Before Taxes-46.44-42.62-42.44-35.28-36.12-37.36-46.78-43.40
Income Taxes0.000.00-1.580.560.850.591.70-2.34
Consolidated Net Income-46.44-42.62-40.85-35.84-36.97-37.95-48.48-41.05
Net Income From Continuing Operations-28.42-20.04-19.23-16.47-16.55-16.73-21.28-17.91
Net Income-28.42-20.04-19.23-16.47-16.55-16.73-21.28-17.91
EPS (Recurring)-0.15-0.14-0.14-0.12-0.13-0.13-0.14-0.14
EPS (Basic, Before Extraordinaries)-0.15-0.14-0.14-0.12-0.13-0.13-0.17-0.14
EPS (Diluted)-0.15-0.14-0.14-0.12-0.13-0.13-0.17-0.14
EBITDA-46.92-43.50-43.92-37.14-38.22-40.00-44.91-47.77
Non-Operating Income (Expense)1.942.332.943.263.594.034.795.58
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.594.944.515.275.175.075.495.48
Price To Sales Ratio465.26285.77352.29439.09146.88369.312,847.53-
Gross Margin-866.00-534.96-544.00-544.24-574.66-501.74-1,664.47-
Operating Margin-32,248.67-19,881.86-20,164.89-17,759.91-17,967.87-17,994.78-60,851.32-
Net Margin-18,948.00-8,865.93-8,547.11-7,589.40-7,489.59-7,275.65-27,997.37-
Shares Outstanding205.72141.98141.81135.98133.42129.54128.05127.92
Market Capitalization236.14254.08317.06326.6976.70113.50216.27242.02

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments270.02358.29362.95490.2520.56
Short Term Receivables1.132.451.380.000.00
Inventories0.000.000.000.000.00
Other Current Assets9.5435.159.8214.476.71
Total Current Assets280.68395.88374.15504.7227.27
Net Property, Plant & Equipment54.9045.1946.4113.0612.60
Total Investments and Advances0.000.000.000.000.00
Intangible Assets0.000.000.000.210.43
Deferred Tax Assets0.001.06---
Other Assets0.000.000.000.000.00
Total Assets335.57442.14420.55518.0040.30
Short Term Debt Incl. Current Port. of LT Debt1.070.770.800.490.27
Accounts Payable0.943.630.000.000.00
Income Tax Payable0.000.681.47--
Other Current Liabilities28.7331.1422.7610.3812.05
Total Current Liabilities30.7436.2225.0410.8712.31
Long Term Debt2.962.473.611.911.07
Provision for Risks Charges0.000.000.000.000.00
Deferred Tax Liabilities0.001.06---
Other Liabilities1.070.750.570.280.00
Total Liabilities34.7840.5029.2213.0613.38
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity-1,011.20-994.95-1,103.40-1,096.6226.92
Total Shareholders Equity-1,011.20-994.95-1,103.40-1,096.6226.92
Accumulated Minority Interest1,311.991,396.591,494.731,601.560.00
Total Equity300.79401.64391.34504.9426.92
Total Liabilities & Stockholders Equity335.57442.14420.55518.0040.30
Book Value Per Share-7.13-7.77-18.43-17.820.44
Tangible Book Value Per Share-7.13-7.77-18.43-17.820.43
Full-Time Employees231204163873
Price to Book Ratio-0.26-0.22-0.10-0.391.31
Return on Assets-17.74-14.18-7.56-28.09-
Return on Invested Capital-----197.06
Quick Ratio9.1310.9314.9446.422.21
Current Ratio9.1310.9314.9446.422.21

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-165.75-151.61-163.34-135.45-148.13-55.15
Depreciation6.856.585.433.853.041.98
Other Funds (Non Cash)21.8923.6427.6024.8574.470.70
Funds from Operations-137.02-121.40-130.31-106.74-70.63-52.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-4.151.283.9616.67-6.462.16
Income Taxes Payable0.17-0.36-0.611.760.280.00
Cash from Operating Activities-141.17-120.12-126.35-90.07-77.09-50.30
Capital Expenditures-18.57-15.20-29.51-34.20-1.85-5.19
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses18.2118.210.000.000.110.00
Purchase or Sale of Investments105.10100.9549.92-295.790.000.00
Purchase of Investments-195.73-217.08-324.02-471.600.000.00
Sale Or Maturity of Investments300.82318.02373.95175.820.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities104.74103.9720.41-329.98-1.74-5.19
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock26.3625.59144.46-9.506.0571.50
Repurchase of Common Pref Stock0.000.000.00-9.500.000.00
Sale of Common Pref Stock26.3625.59144.460.006.0571.50
Proceedsfrom Stock Options24.2524.25144.460.006.0571.50
Issuance or Reduction of Debt, Net-0.01-0.03-0.05-0.05-0.03-0.03
Change in Long Term Debt-0.01-0.03-0.05-0.05-0.03-0.03
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.01-0.03-0.05-0.05-0.03-0.03
Net Financing Active Other Cash Flow0.000.000.000.00542.500.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities26.3525.57144.41-9.55548.5271.47
Net Change in Cash-10.079.4238.47-429.60469.6915.98
Free Cash Flow-159.73-135.31-155.86-124.27-78.94-55.49
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments181.56224.94270.02271.73294.73328.50
Short Term Receivables0.961.031.131.241.771.75
Inventories0.000.000.000.000.000.00
Other Current Assets7.258.939.5427.0327.9429.41
Total Current Assets189.77234.90280.68299.99324.44359.66
Net Property, Plant & Equipment59.2557.8854.9051.6247.6946.40
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets--0.00---
Other Assets0.000.000.000.000.000.00
Total Assets249.02292.78335.57351.61372.13406.06
Short Term Debt Incl. Current Port. of LT Debt1.131.111.070.990.900.86
Accounts Payable1.612.590.941.942.443.12
Income Tax Payable-0.000.000.060.001.26
Other Current Liabilities19.9722.2328.7326.0724.9227.57
Total Current Liabilities22.7125.9330.7429.0628.2632.81
Long Term Debt2.392.672.963.253.522.51
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.00---
Other Liabilities1.071.071.070.960.900.76
Total Liabilities26.1829.6834.7833.2732.6836.08
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-883.53-1,023.78-1,011.20-1,008.02-1,002.50-998.55
Total Shareholders Equity-883.53-1,023.78-1,011.20-1,008.02-1,002.50-998.55
Accumulated Minority Interest1,106.371,286.891,311.991,326.361,341.951,368.53
Total Equity222.84263.10300.79318.34339.45369.98
Total Liabilities & Stockholders Equity249.02292.78335.57351.61372.13406.06
Book Value Per Share-4.29-7.21-7.13-7.41-7.51-7.71
Tangible Book Value Per Share-4.29-7.21-7.13-7.41-7.51-7.71
Full-Time Employees--231---
Price to Book Ratio-0.26-0.25-0.30-0.32-0.08-0.11
Return on Assets-27.10-20.69-17.74-17.19-16.64-17.24
Quick Ratio8.369.069.1310.3211.4810.96
Current Ratio8.369.069.1310.3211.4810.96

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-46.44-42.62-40.85-35.84-36.97-37.95
Depreciation1.681.661.841.671.471.60
Other Funds (Non Cash)5.344.535.756.275.975.65
Funds from Operations-39.42-36.43-33.27-27.90-29.52-30.70
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.95-5.250.761.30-1.891.11
Income Taxes Payable0.000.000.050.12-1.120.59
Cash from Operating Activities-40.37-41.68-32.51-26.60-31.42-29.59
Capital Expenditures-3.83-3.79-5.75-5.20-3.11-1.14
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.0018.210.000.000.00
Purchase or Sale of Investments16.6438.6115.6334.2221.6829.42
Purchase of Investments-32.03-44.75-40.40-78.54-42.69-55.45
Sale Or Maturity of Investments48.6783.3756.03112.7564.3784.87
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities12.8134.8328.0929.0218.5728.29
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.550.2217.647.960.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.550.2217.647.960.000.00
Proceedsfrom Stock Options0.000.0117.147.100.000.00
Issuance or Reduction of Debt, Net-0.01-0.00-0.010.01-0.01-0.01
Change in Long Term Debt-0.01-0.00-0.010.01-0.01-0.01
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.01-0.00-0.010.01-0.01-0.01
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.540.2117.637.96-0.01-0.01
Net Change in Cash-27.03-6.6413.2110.38-12.87-1.31
Free Cash Flow-44.21-45.47-38.27-31.79-34.53-30.73

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 76.00K 2025: 893.00K
United States2024: 76.00K 2025: 893.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.70%24.3M112.1M1.32M
2026-10-1521.91%24.6M112.1M1.30M
2026-09-3021.22%23.8M112.1M1.32M
2026-09-1537.42%21.4M57.3M1.27M
2026-08-3136.18%20.7M57.3M1.24M
2026-08-1438.29%21.5M56.1M1.21M
2026-07-3136.79%20.7M56.3M1.15M
2026-07-1537.15%20.9M56.3M1.10M
2026-06-3034.51%19.4M56.3M1.12M
2026-06-1531.17%17.5M56.3M946.69K
2026-05-2931.89%18.0M56.5M886.63K
2026-05-1549.17%19.2M39.1M818.07K
2026-04-3042.65%18.3M42.8M857.31K
2026-04-1516.99%17.6M103.6M919.25K
2026-03-3116.10%16.7M103.6M868.48K
2026-03-1314.80%15.3M103.6M952.72K
2026-02-2715.06%15.6M103.3M1.04M
2026-02-1315.68%16.2M103.3M1.15M
2026-01-3015.11%15.6M103.3M1.28M
2026-01-1514.76%15.3M103.3M1.35M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.151.150.550.00020.000.000.0000.0000.000
call1.000.001.000.7519.8135.000.000.956-0.0180.000
call1.500.001.000.188.59114.000.000.685-0.0310.001
call2.000.000.350.057.87054.000.000.558-0.0310.001
call3.000.000.650.059.3841190.000.525-0.0370.001
call4.000.000.300.009.6260.000.000.462-0.0380.001
call5.000.001.000.105.8651.000.000.132-0.0130.000
put0.500.001.000.000.0000.000.000.0000.0000.000
put1.000.000.950.3325.6352.000.00-0.021-0.0130.000
put1.500.101.100.2012.0945.000.00-0.060-0.0250.000
put2.000.451.450.0012.2900.000.00-0.442-0.0310.001
put3.001.402.400.0012.8830.000.00-0.475-0.0370.001
put4.002.403.400.0013.8200.000.00-0.198-0.0420.001
put5.003.404.400.0014.4670.000.00-0.202-0.0430.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-29S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-103Initial statement of beneficial ownership of securities2026-06-01SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-298-KCurrent report2026-05-28SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-30SCHEDULE 13D/ASEC
2026-04-304Statement of changes in beneficial ownership of securities2026-04-28SEC
2026-04-17ARSAnnual report to security holders. 2025-12-31SEC
2026-04-17DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-17DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-28SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08001.07M6
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-11001.88M2

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC6.01%
MORGAN STANLEY4.80%
BlackRock, Inc.2.53%
GEODE CAPITAL MANAGEMENT, LLC1.72%
Bleichroeder LP0.97%
Artia Global Partners LP0.88%
Hennion & Walsh Asset Management, Inc.0.86%
VANGUARD CAPITAL MANAGEMENT LLC0.57%
RENAISSANCE TECHNOLOGIES LLC0.54%
MILLENNIUM MANAGEMENT LLC0.51%

Funds

Fund% owned
iShares Russell 2000 ETF0.84%
VANGUARD EXTENDED MARKET INDEX FUND0.57%
Morgan Stanley Insight Fund0.55%
Morgan Stanley Discovery Portfolio0.53%
Fidelity Small Cap Index Fund0.40%
Discovery Portfolio0.40%
Schwab U.S. Small-Cap ETF0.24%
iShares Russell 2000 Growth ETF0.22%
VANGUARD RUSSELL 2000 INDEX FUND0.21%
Fidelity Extended Market Index Fund0.19%

OakChart. PROK. Cached 15 minutes.